The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
about
Interventions for enhancing medication adherenceInterventions for enhancing medication adherenceSchizophreniaCognitive enhancement in schizophrenia: pharmacological and cognitive remediation approachesFeasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset SchizophreniaDevelopment and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications.Engagement-focused care during transitions from inpatient and emergency psychiatric facilities.Neurocognitive impairment and HIV risk factors: a reciprocal relationship.International assessment of functional skills in people with schizophrenia.Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illnessModeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.Strategies to improve medication adherence in patients with schizophrenia: the role of support services.The sensitivity and specificity of cognitive screening instruments to detect cognitive impairment in older adults with severe psychiatric illnessA randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.The cultural adaptability of intermediate measures of functional outcome in schizophreniaNeurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence.Effectiveness of specific intervention on treatment adherence of persons with mental illness: A pilot study.Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia.A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophreniaToward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?A review of behavioral tailoring strategies for improving medication adherence in serious mental illness.Cognitive remediation: a promising tool for the treatment of schizophrenia.The "Critical" Elements of Illness Management and Recovery: Comparing Methodological ApproachesImplicit versus explicit attitudes toward psychiatric medication: Implications for insight and treatment adherence.Denial and acceptance coping styles and medication adherence in schizophrenia.The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia.Measurement of psychiatric treatment adherencePharmacological treatment of schizophrenia.Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.Cognitive remediation in schizophrenia: current status and future perspectives.Effectiveness and cost-effectiveness of cognitive adaptation training as a nursing intervention in long-term residential patients with severe mental illness: study protocol for a randomized controlled trial.Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.Illness management and recovery in community practice.Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives.The treatment of schizophrenia: Can we raise the standard of care?Conceptualization and treatment of negative symptoms in schizophrenia.Medication-taking behaviours in young adults with schizophrenia: a pilot study.
P2860
Q24187912-485D2B98-922B-429C-B54E-020014EEA0DDQ24243296-C2140713-0892-488A-B54D-EEA5B4FAD164Q24596536-48A75326-6D8C-43A2-9042-F064CEFEF613Q26864324-1024030A-17ED-44B9-B3A3-DFBAC97570C2Q33448465-FF1A8BD5-E249-475D-BA48-C7B717AA8B68Q33449854-9A8FFFD5-DEBD-4858-93A3-DCBCB04D0F3DQ33714101-85BBEA13-1001-461D-990B-DA9917A99E75Q34005620-EF5FFC60-F2C7-446E-9777-8EF3457597FEQ34564057-5C4E21C5-DC9F-49A3-A482-CFF5EDD318CAQ34650576-D9D85879-8EC2-45F1-9088-A16A6C5942E5Q35065381-DBB4A289-2FF0-47A4-9B2B-CE4085EA4417Q35370011-7C014EEA-DD0B-46D0-BF54-EDC535BC5CF1Q35507000-378391F1-364A-4F2D-9458-C07AA5BF4183Q35617305-7EEAF4F8-48A7-4EFF-9674-7224967E0994Q35794290-21AEE79D-FC35-4280-8C86-2DC37580F82EQ35898719-465203B8-1BC2-4FA8-8FE1-5F11EF9A0B64Q36169003-9C5F45A5-AE77-4FA1-8DE2-6A6BB3C631BAQ36458087-4AAD3CD9-BBBB-49DB-8C48-97B3EF10692AQ36915104-E377DFC9-9556-42F3-A751-CD5BA8A96C30Q37131062-8E05E914-FBDB-41C2-B89E-77BDCD0F455CQ37137026-79514BD0-6954-4BA4-8D15-271F6640B874Q37144812-D5E39B61-F2DB-49EF-99D0-3B02CBDDDD22Q37203349-39B83560-F2A0-4F38-88CC-B3A9AF49C1CBQ37241477-68CC469B-10E0-44AE-902A-8BAA14A9C468Q37348949-8D3C3BE9-CD62-47ED-8979-0BFE7F189D42Q37353847-8C1D049D-5D77-4F78-A7C6-0CE801B40E7DQ37363543-11B4F2EE-05EF-456E-940D-CE90C9F66F9DQ37594717-21C1499F-72C2-4433-AE37-D8C1E350379BQ38051438-F66DDCDC-9600-48BF-9D02-82A4AF0B6CEEQ38133770-B895A9C7-4432-4902-A25A-569006672399Q38181123-5586D6EE-DBB6-48A4-B307-3402CA562EC6Q38412991-E85CA0ED-AF45-4D3F-A339-DA6B045BD523Q38578316-BCFB9429-209F-468A-94D3-8E416DE071CCQ38815462-964F9D11-5179-490D-8E1B-56BBCBCC5A50Q38852539-446E9044-5399-420B-BEAA-4238F2D76613Q38922889-CA04F8D4-F820-4784-BD7B-9BD95FE8CD65Q38971750-16FAA693-B28E-48FE-A519-6BAFC3983441Q39002140-58375FB7-1ECD-44A3-81FF-08FC09112E4EQ39178474-F04C5D46-CA30-4A41-B8C6-1D21357DC54BQ39754439-4BA6C6EF-FECD-4141-BE68-4CC3AAC0DADB
P2860
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of individually tailor ...... and outcomes in schizophrenia.
@en
The use of individually tailor ...... and outcomes in schizophrenia.
@nl
type
label
The use of individually tailor ...... and outcomes in schizophrenia.
@en
The use of individually tailor ...... and outcomes in schizophrenia.
@nl
prefLabel
The use of individually tailor ...... and outcomes in schizophrenia.
@en
The use of individually tailor ...... and outcomes in schizophrenia.
@nl
P2093
P2860
P356
P1476
The use of individually tailor ...... and outcomes in schizophrenia.
@en
P2093
Alexander L Miller
Dawn I Velligan
Desiree Castillo
John Zeber
Larry Ereshefsky
Natalie Maples
Pamela M Diamond
Xueying Li
Yui-Wing F Lam
P2860
P304
P356
10.1093/SCHBUL/SBM111
P407
P577
2007-10-10T00:00:00Z